Sign In
Buy REGN
$618.95
+16.03 (+2.66%)
At Close: Jun 03, 2026
Regeneron: Catching Another Wind
10:20am, Monday, 27'th Apr 2026
Regeneron has rebounded from regulatory and clinical setbacks, with Dupixent, Lynozyfic, and cemdisiran driving renewed growth momentum. REGN's pipeline is robust, targeting obesity, complement-mediat
Regeneron Pharmaceuticals Details C5 Strategy, With PNH Data Due Q4 and gMG NDA Under Review
02:36am, Monday, 27'th Apr 2026
Regeneron Pharmaceuticals (NASDAQ: REGN) outlined its C5 complement development strategy in an investor roundtable focused on cemdisiran, an siRNA targeting C5, and pozelimab, a C5-targeting antibody
Regeneron weighs overseas price for Otarmeni, gene therapy for rare type of hearing loss
02:37pm, Friday, 24'th Apr 2026
Regeneron will make its newly approved gene therapy Otarmeni for a rare, genetic form of hearing loss available for free in the U.S. The company hasn't decided how it will price the therapy overseas,
Regeneron Strikes Deal With Trump Administration To Cut Drug Prices
12:08pm, Friday, 24'th Apr 2026
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) has reached an agreement with the U.S. government to lower drug prices, expand patient access, and provide a newly approved gene therapy at no cost, aligni
Regeneron CEO on deal with Trump admin to lower drug prices
10:30am, Friday, 24'th Apr 2026
Regeneron inked a deal with the Trump administration to lower drug prices and avoid planned tariffs. CEO Leonard Schleifer told CNBC's "Squawk Box" on Friday that "we have to support this industry," b
Gear Up for Regeneron (REGN) Q1 Earnings: Wall Street Estimates for Key Metrics
10:16am, Friday, 24'th Apr 2026
Get a deeper insight into the potential performance of Regeneron (REGN) for the quarter ended March 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for som
Regeneron will provide Otarmeni™ (lunsotogene parvec-cwha) , its recently approved gene therapy for an ultra-rare form of genetic hearing loss, for free in the U.S.
Regeneron inks drug pricing deal with Trump, will offer new hearing-loss therapy for free
03:40pm, Thursday, 23'rd Apr 2026
Regeneron agreed to lower U.S. drug prices for some Americans as part of a deal with President Donald Trump. The biotech company will also offer the first hearing-loss gene therapy for free to eligibl
Regeneron to offer prescriptions at most favored nation prices, Trump says
03:21pm, Thursday, 23'rd Apr 2026
U.S. President Donald Trump said on Thursday that Regeneron has agreed to offer prescriptions at most favored nation prices.
SNY & REGN's Dupixent Wins FDA Nod for Pediatric Use in Urticaria
02:30pm, Thursday, 23'rd Apr 2026
Sanofi wins FDA nod to expand Dupixent in kids aged 2-11 years, marking the first biologic for young patients with uncontrolled CSU.
FDA Approves First-Ever Gene Therapy to Restore Hearing
01:42pm, Thursday, 23'rd Apr 2026
Regeneron's drug restored hearing in 11 of 12 children in a rare, inherited condition that causes deafness.
FDA approves Regeneron's gene therapy for inherited deafness
12:45pm, Thursday, 23'rd Apr 2026
U.S. Food and Drug Administration has approved Regeneron's gene therapy for a rare genetic form of deafness, the company said on Thursday.
Approval in severe-to-profound and profound OTOF -related hearing loss is based on pivotal results of the CHORD trial demonstrating 80% of participants achieved or surpassed a hearing level meeting
White House to announce drug pricing deal with Regeneron, source says
12:00pm, Thursday, 23'rd Apr 2026
The White House will announce a drug pricing deal with Regeneron Pharmaceuticals on Thursday, according to a source familiar with the matter.
Regeneron Pharmaceuticals, Inc. (REGN) Discusses C5 Complement Development Program Focusing on Cemdisiran and Pozelimab for Complement-Mediated Diseases Transcript
